María G. Crespo‐Leiro
A5020567566- Transplantation: Methods and Outcomes
- Cardiac Structural Anomalies and Repair
- Mechanical Circulatory Support Devices
- Heart Failure Treatment and Management
- Renal Transplantation Outcomes and Treatments
- Viral Infections and Immunology Research
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Organ Transplantation Techniques and Outcomes
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrest and Resuscitation
- Cardiomyopathy and Myosin Studies
- Viral-associated cancers and disorders
- Potassium and Related Disorders
- Cardiac Arrhythmias and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Cardiac Valve Diseases and Treatments
- Organ and Tissue Transplantation Research
- Parathyroid Disorders and Treatments
- Pulmonary Hypertension Research and Treatments
- Diabetes Treatment and Management
- Cardiac electrophysiology and arrhythmias
Instituto de Investigación Biomédica de A Coruña
2016-2025
Centro de Investigación Biomédica en Red
2017-2025
Centro de Investigación en Red en Enfermedades Cardiovasculares
2017-2025
Complexo Hospitalario Universitario A Coruña
2016-2025
Universidade da Coruña
2016-2025
Instituto de Salud Carlos III
2012-2024
Servicio Gallego de Salud
2015-2024
Clinica Universidad de Navarra
2023
University of Milan
2023
IRCCS Policlinico San Donato
2023
à Use of Class III is discouraged by the ESC. Levels EvidenceLevel Evidence A Data derived from multiple randomized clinical trials or meta-analyses Level B a single trial large nonrandomized studies C Consensus opinion experts and/or small studies; retrospective and registriesFigure 1 Clinical classification mode heart failure (Forrester classification).H I-IV refers to haemodynamic severity, with reference figures for CI pulmonary capillary pressures shown on vertical horizontal axes,...
Poland), and Katja Zeppenfeld (
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve function in patients with heart failure a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.We randomly assigned 8256 (inpatients and outpatients) symptomatic chronic an fraction of 35% or less receive (using pharmacokinetic-guided doses 25 mg, 37.5 50 mg twice daily) placebo, addition standard heart-failure therapy. primary outcome was composite first event (hospitalization urgent...
Numerous genes are known to cause dilated cardiomyopathy (DCM). However, until now technological limitations have hindered elucidation of the contribution all clinically relevant disease DCM phenotypes in larger cohorts. We utilized next-generation sequencing overcome these and screened a large cohort. In this multi-centre, multi-national study, we enrolled 639 patients with sporadic or familial DCM. To samples, applied standardized protocol for ultra-high coverage 84 genes, leading 99.1%...
Abstract Long-term mechanical circulatory support (LT-MCS) is an important treatment modality for patients with severe heart failure. Different devices are available, and many—sometimes contradictory—observations regarding patient selection, surgical techniques, perioperative management follow-up have been published. With the growing expertise in this field, European Association Cardio-Thoracic Surgery (EACTS) recognized a need structured multidisciplinary consensus about approach to LT-MCS....
To investigate the characteristics long-term prognostic implications (up to ∼2.2 years) of atrial fibrillation (AF) compared sinus rhythm (SR), between acute and chronic heart failure (HF) with reduced (HFrEF < 40%), mid-range (HFmrEF 40–49%), preserved (HFpEF ≥ 50%) ejection fraction (EF). Data from observational, prospective, HF registry European Society Cardiology were analysed. A total 14 964 patients (age 66 ± 13 years, 67% male; 53% HFrEF, 21% HFmrEF, 26% HFpEF) enrolled. The...
Serelaxin is a recombinant form of human relaxin-2, vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested treatment with serelaxin may result in relief symptoms better outcomes patients acute heart failure.In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled who were hospitalized for failure had dyspnea, vascular congestion on chest radiography, increased plasma concentrations...
The use of circulating cell-free DNA (cfDNA) as a biomarker in transplant recipients offers advantages over invasive tissue biopsy quantitative measure for detection rejection and immunosuppression optimization. However, the fraction donor-derived cfDNA (dd-cfDNA) recipient plasma is low challenging to quantify. Previously reported methods dd-cfDNA require donor genotyping, which impractical clinical settings adds cost. We developed targeted next-generation sequencing assay that uses 266...